# Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine

> **NCT01728025** · PHASE2 · UNKNOWN · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 10 (estimated)

## Conditions studied

- Long QT Syndrome Type 3

## Interventions

- **DRUG:** Ranolazine

## Key facts

- **NCT ID:** NCT01728025
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-10
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2015-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01728025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01728025, "Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine". Retrieved via MORVS 2026-10-30 from https://api.morvs.ai/clinical/NCT01728025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*